🇺🇸 FDA
Patent

US 12398140

Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia

granted A61PA61P25/00

Quick answer

US patent 12398140 (Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia) held by PTC THERAPEUTICS, INC. expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61P, A61P25/00